Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06668103 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary completion date: Jun 30, 2027 to Dec 30, 2027 · Start date changed from estimate of Dec 30, 2025 to Nov 25, 2024 · Site details revised at 5 of 5 sitesv3 Show 3 more changesShow less
    • Primary completion date: Jun 30, 2027 to Dec 30, 2027
    • Start date changed from estimate of Dec 30, 2025 to Nov 25, 2024
    • Site details revised at 5 of 5 sites
  2. Secondary endpoints: details revised at 15 of 16 entries Eligibility criteria shortened, about 1 wordv2 Show 1 more changeShow less
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label phase 2 study to evaluate the safety, tolerability and preliminary anti-tumour activity of ABSK043 in combination with Firmonertinib in patients with Epidermal Growth Factor Receptor-mutated (EGFRm+) locally advanced or metastatic NSCLC.
Trial Details
NCT Number NCT06668103
Lead Sponsor Abbisko Therapeutics Co, Ltd
Conditions Non-Small Cell Lung Cancer With EGFR Mutation
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov